Immuneering Corporation (IMRX)
| Market Cap | 229.59M -43.1% |
| Revenue (ttm) | n/a |
| Net Income | -66.50M |
| EPS | -1.03 |
| Shares Out | 64.76M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,552 |
| Open | 3.410 |
| Previous Close | 3.370 |
| Day's Range | 3.368 - 3.545 |
| 52-Week Range | 3.350 - 8.480 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+379.55%) |
| Earnings Date | Oct 29, 2026 |
About IMRX
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinica... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for IMRX stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 379.55% from the latest price.
News
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026
- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival ...
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today annou...
Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
Immuneering reports Q3 EPS (37c), consensus (31c)
“We are thrilled to share that follow-up in our Phase 2 trial in first-line pancreatic cancer is being extended because patients are living longer than projected. We now plan to…
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the...
Immuneering Earnings release: Q3 2026
Immuneering released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Immuneering Quarterly report: Q3 2026
Immuneering has published its Q3 2026 quarterly earnings report on October 29, 2026.
Immuneering price target lowered to $11 from $12 at Mizuho
Mizuho lowered the firm’s price target on Immuneering (IMRX) to $11 from $12 and keeps an Outperform rating on the shares.
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKe...
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combinat...
3 ‘Strong Buy’ Stocks Under $10 to Watch in October for 100%+ Upside
Low-priced stocks can carry high risk but also offer solid upside potential. On Wall Street, analysts currently rate three such stocks a Strong Buy: Perspective Therapeutics ($CATX), Immuneering ($IMR...
Immuneering presents new data at 2026 AACR on atebimetinib
Immuneering (IMRX) announced the presentation of new data at the 2026 AACR Conference on Pancreatic Cancer in San Diego, California. The findings support a potential dual mechanism of action through…
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -
Immuneering to Present at the ESMO Congress 2026
NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Atebimetinib, a third-generation MEK inhibitor, is in phase III for first-line pancreatic cancer, showing a median OS of 17.3 months and strong tolerability. Its unique mechanism and synergy with mutation-specific RAS inhibitors position it as a promising option in a major unmet need.
Immuneering Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Atebimetinib, a novel MEK inhibitor, shows strong efficacy and tolerability in first-line pancreatic cancer, nearly doubling median overall survival compared to standard care. Ongoing phase III trials and upcoming data updates aim to further validate its differentiated profile.
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival
- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the ...
Immuneering to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today anno...
Immuneering says FDA approval of pancreatic cancer treatment ‘good news’
Immuneering (IMRX) Corporation shared comments following the recent FDA approval of a new second-line pancreatic cancer treatment. “Approval of this new treatment is good news for the subset of pancre...
Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
- For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic cancer...
Immuneering initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Immuneering (IMRX) with a Buy rating and $14 price target The firm says the company’s atebimetinib appears capable of delivering substantial pathway inhibition wi...
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on Jun...
Immuneering Earnings release: Q2 2026
Immuneering released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Immuneering Quarterly report: Q2 2026
Immuneering has published its Q2 2026 quarterly earnings report on August 5, 2026.
Immuneering publishes preclinical data on atebimetinib in Cancer Research
Immuneering (IMRX) announced the publication of new findings in Cancer Research, a journal of the American Association for Cancer Research, characterizing the mechanism and preclinical activity of ate...